The Health Resources and Services Administration (HRSA) has issued a clarification notice on the registration requirements for offsite hospital outpatient facilities in accordance with the 340B drug pricing program. According to JD Supra, this statement, which was slated to be published in the Federal Register on October 27, clears the ambiguity created in hospitals following the conclusion of the COVID-19 public health emergency (PHE) in May.
During the COVID-19 PHE, the HRSA had apparently hinted on its website that hospitals could utilize 340B drugs in their new clinics. However, following the end of the PHE, this assertion was removed, leaving hospitals uncertain about the guidelines regarding the usage of 340B drugs.
The main purpose of the 340B program is to provide economically vulnerable patients access to prescription medications. It allows hospitals to obtain outpatient drugs at heavily discounted prices, contributing to cost savings that can be redirected towards other critical patient care services.
The HRSA’s recent clarification serves as a guiding document for offsite hospital outpatient facilities, ensuring adherence to the 340B program’s regulations. It further emphasizes the discontinuation of the previously extended COVID-19 “waiver” that fostered understanding amidst the pandemic’s turmoil.